CartilaGen Overview

  • Founded
  • 2014
  • Status
  • Private
  • Latest Deal Type
  • Grant
  • Latest Deal Amount
  • $25K
Latest Deal Amount
  • Investors
  • 5

CartilaGen General Information


Developer of cost-effective biological joint replacement intended to be used for several unique OA and cartilage repair techniques. The company's offerings include drug-eluting biomaterials, disease-modifying therapeutics and wearable drug delivery devices to treat knee osteoarthritis (OA), enabling patients to receive preventative treatment.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Medical Supplies
Other Industries
Therapeutic Devices
Primary Office
  • 2501 Crosspark Road
  • Unit E156M
  • Coralville, IA
  • United States
Want detailed data on 2M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

CartilaGen Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Grant 16-Sep-2019 $25K Completed Generating Revenue
4. Later Stage VC Completed Startup
3. Grant 02-May-2016 000 Completed Startup
2. Grant 30-Apr-2016 $5K Completed Startup
1. Grant 10-Apr-2016 $2K Completed Startup
To view CartilaGen’s complete valuation and funding history, request access »

CartilaGen Executive Team (2)

Name Title Board Seat Contact Info
Jaison Marks Co-Founder & Chief Executive Officer
Frank Yu Ph.D Co-Founder
To view CartilaGen’s complete executive team members history, request access »

CartilaGen Investors (5)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
University of Iowa Research Foundation Limited Partner 000 0000 000000 0
Columbia University Graduate School of Business Other 000 0000 000000 0
The Chinese University of Hong Kong University 000 0000 000000 0
Harvard University Endowment Limited Partner 000 0000 000000 0
EGI Capital Venture Capital Minority 000 0000 000000 0
To view CartilaGen’s complete investors history, request access »